Luís Pinho, Maria Manuela Rodrigues, Jéssica Estrela, Ricardo Jorge Teixo, Fernando K and Rui Santos Cruz
Lung cancer presents a heterogeneous nature, which became more and more evident. Generally this type of cancer in an advanced state has a poor prognosis. The discovery of multiple molecular mechanisms, associated to the development, proliferation and prognosis of lung cancer has created new opportunities for a targeted therapy, improving clinical results. Non-small cells lung cancer is characterized by mutations on Epidermal Growth Factor Receptor and/or in the signaling pathways related to this receptor, which promoted the development of selective monoclonal antibodies and Epidermal Growth Factor Receptor-Tirosine Kinase Inhibitors, blocking the proliferation, differentiation, angiogenesis and tumor survival. Thus, our review highlighted the importance of a continuous research of new molecular targets in lung cancer to achieve better therapeutic outcomes and overall survival rates.
PDFShare this article
Journal of Integrative Oncology received 495 citations as per Google Scholar report
